tbuckley/cabot-search huggingface dataset:
Rural challenges in a decade of crowdfunding for cancer care.
Authors: Ahmed Khalil, Sheetal L. Higbee, Khalid Khasawinah
Journal: Journal of Clinical Oncology (2020)

e14013 Background: Improving access and affordability to oncology care for patients in rural America is a national imperative given growing health disparities in cancer morbidity and mortality. Crowdfunding has emerged as a rescue tool for cancer patients facing difficulties paying for treatment costs. While such platforms present opportunities to increase access, patients who live in rural areas face increased challenges compared to those in urban areas. Methods: We crawled the pages of GoFundMe fundraising campaigns from 2010 – 2020 using a custom Python script. We then indexed these pages for campaigns focused on cancer treatment in the US and identified variables of interest using text analysis, including cancer type, demographics, clinical characteristics, and social network features, resulting in 151,051 campaigns. Rural status was identified by analyzing zip codes against the database provided by the US Census. Descriptive statistics, χ2, and t-tests were used to compare variables by rural status using R 3.6.3 software. Results: The 10 most prevalent types of cancer in our data were metastatic (26.8%), breast (17.0%), lung (12.4%), colorectal (6.6%), brain (6.3%), liver (4.2%), leukemia (3.2%), stomach (2.7%), pancreas (2.6%), and bone (2.1%). We found a statically significant difference between urban and rural areas in key variables including unemployment rate, insurance status, metastatic cancer rate, treatment type, social network reach, and fundraising totals. Conclusions: Since the 2011 launch of (ASCO) task force for improving cancer care of rural patients, a tremendous effort has been directed towards that. In our study of 151,051 patients over a 10-year period, we found that disparities between rural and urban America in cancer are not just limited to clinical management, but also in an era of crowdfunding, rural patients are still struggling to get the attention they need. We must increase efforts to raise awareness and find solutions to improve access to cancer care. [Table: see text]
以窦房传导阻滞为特点的甲状腺功能亢进症一例
Authors: 张宜春
Journal: BMJ (2007)

患者女,38岁,因反复发作性头晕、晕厥2年于2006年8月11日入院.2年前患者出现发作性头晕,多次活动时突发眼前发黑,随之意识不清,历时约1 min能自行缓解.在当地医院测血压185/80 mm Hg(1 mm Hg=0.133 kPa),一直以高血压病诊治,但病情渐加重.发病以来,患者体重下降、多汗、乏力,未服用β受体阻滞剂等减慢心率药物。
冠状动脉造影正常就没有冠心病吗
Authors: 许玉韵
Journal: BMJ (2005)

一、心绞痛诊断主要靠什么? 心绞痛主要靠详细而准确的病史,结合常规12导联心电图.如不能肯定是否存在心肌缺血(症状性及无症状性),首先考虑做无创性的心电图运动试验或药物负荷试验,而不应是冠状动脉造影(冠脉造影),更不应该以冠脉造影是阳性或阴性作出最后的肯定诊断。
Whole-exome sequencing identifies rare variants in STAB2 associated with venous thromboembolic disease
Authors: Karl C. Desch, Ayse B. Ozel, Matt Halvorsen, Paula M. Jacobi, Krista Golden, Mary Underwood, Marine Germain, David-Alexandre Tregouet, Pieter H. Reitsma, Clive Kearon, Lauren Mokry, J. Brent Richards, Frances Williams, Jun Z. Li, David Goldstein, David Ginsburg
Journal: Blood (2020)
Chinese Obstetrics & Gynecology journal club: a randomised controlled trial
Authors: Tsui Ilene K, Dodson William C, Kunselman Allen R, 匡洪影, 韩凤娟, Legro Richard S, 吴效科, 常惠
Journal: BMJ (2016)

目的
评价期刊俱乐部这种教学模式是否能提高中国医疗职业人群的医学英语的理解、写作和口语能力。


背景和受试者
此项研究包括52名医疗职业的受试者，来自中国黑龙江中医药大学妇产科专业的住院医生、博士或者硕士研究生。


干预
通过3部分基线测试来评估受试者医学英语的理解能力，然后随机分为2组：（1）期刊俱乐部组；（2）自学组。8周后，再次测试得出结论。


结局指标
主要结局指标：多项选择题测试干预前后分数的变化。次要结局指标：包括写作和口语测试分数的变化，考试形式模拟鉴定非英语为母语者的英语能力（TOEFL，托福）考试进行的。


结果
2组的多项选择题测试均提高，但没有明显的统计学差异（90%效力）。但是，在写作[95%可信区间（CI）1.1~5.0；P=0.003]和口语测试（95%CI 0.06~3.7；P=0.04）方面，2组均有提高，且期刊俱乐部组更明显，且差异有统计学意义。


结论
中国医疗职业人员与学生和主持者进行英语交流，能提高医学英语的写作水平和口语技能；在非英语国家的医疗职业人群中，期刊俱乐部可能是一种提高医学英语水平的持续的教学模式。


试验注册号码
NCT01844609。
呕吐咖啡色液体、排黑便一天
Authors: 刘海燕, 龚玮华, 祝墡珠
Journal: BMJ (2012)

病史摘要患者,女性,89岁.因“呕吐咖啡色液体、排黑便1d”于2010年8月23日就诊.1d前患者鼻饲流质食物300 ml,约半小时后呕吐一次,呕吐物为深棕色无臭黏液,量约80 ml.次日晨呕吐咖啡色液体2次,总量约50 ml,排软、黑便3次,总量约100ml.呕吐非喷射样,无鲜血,无腹痛、腹泻,无脓血便,无发热,无皮肤、黏膜黄染,无意识障碍.病程中患者食欲差,烦躁不安.入院以上消化道出血待查收入病房.发病前1d因低热服用酚氨咖敏片。
2006版全球哮喘防治创议的关键信息
Authors: 迟春花
Journal: BMJ (2007)

全球哮喘防治创议(GINA)是指导哮喘规范化诊断和治疗的重要文件.自1993年问世以来,大大推动了全球哮喘管理工作的进步,使众多哮喘患者从中获益.但是国际性调查显示,尽管经过广泛努力,并且已有很多有效的疗法,但许多国家的哮喘控制仍不理想.我国也仍有几千万哮喘患者至今还在忍受哮喘的折磨,其主要原因是没有得到规范化的治疗。
Adjuvant treatments for hepatocellular carcinoma after radical resection
Authors: Jianbo Xu, Gang Xu, Jianhuai Zhang, Mingde Huang
Journal: BMJ (2017)

The high incidence of postoperative recurrence of hepatocellular carcinoma (HCC) is a most difficult obstacle for improving the prognosis of patients.Several adjuvant modalities have been developed to prevent recurrence in patients after surgery; nevertheless, there is no consensus regarding the standardized adjuvant therapy in terms of indications, clinical efficacy and interactions.In this article we review the currently available evidence in the medical literature on adjuvant therapy in HCC after radical resection.


Key words: 
Neoadjuvant therapy; Carcinoma, hepatocellular
Survey on home blood pressure measurement and blood pressure control rate among hypertensive patients in Beijing Yuetan community
Authors: Lili Bian, Yuming Dong, Hongying Zhao, Beibei Song, Qingyun Xue, Peipei Wang, Jing Li
Journal: BMJ (2020)

Objective
To survey on the home blood pressure measurement and blood pressure control rate among patients with hypertension in Beijing Yuetan community.


Methods
A questionnaire survey was conducted among 504 hypertensive patients, who were visiting Beijing Yuetan Community Health Service Center and selected by convenience-sampling method during June 2018 to January 2019. The status of home blood pressure measurement, the awareness of hypertension, the blood pressure control rate and factors related to not regularly measuring were surveyed.


Results
Of the 504 patients, 93.7% (472/504) took regular medication, but only 61.5% (310/504) had regular blood pressure measurements; 92.5% (466/504) had sphygmomanometers at home with electronic type mainly; 89.9% (453/504) patients knew the method of blood pressure measurement, but only 11.5% (52/453) had their sphygmomanometer calibrated. Among those who measured blood pressure, 77.4% (240/310) measured per week. The main reason for not measuring blood pressure regularly was that there was no need to measure blood pressure without any discomfort, accounting for 50.0% (97/194). The office blood pressure control rate (with desktop mercury sphygmomanometer) was 62.3% (314/504); the blood pressure control rate both in the morning and at bed time was 61.3% (73/119), that in the morning was 68.1% (81/119) and at bed time was 75.6% (90/119). The control rates of systolic blood pressure and heart rate by home measurement at morning and bedtime were significantly higher than those by office measurement (χ2=5.02, 9.97, 15.51, 13.72; all P<0.05).


Conclusions
The home blood pressure monitoring rate and knowledge level of hypertension among patients with hypertension in Yuetan community are relatively low. There are some differences in blood pressure control rate between office measurement and home measurement. Comprehensive evaluation is needed in the management process, and the treatment plan should be adjusted according to the specific condition of patients.


Key words: 
Hypertension; Home blood pressure measurement; Blood pressure control rate
Outcomes in older patients with high-risk/secondary AML who achieved remission with CPX-351 versus 7+3 but did not undergo transplant: Phase 3 exploratory analysis.
Authors: Tara L. Lin, Robert J Ryan, Stefan Faderl, Ellen K. Ritchie
Journal: Journal of Clinical Oncology (2020)

7537 Background: CPX-351 (Vyxeos; daunorubicin [D] and cytarabine [C] liposome for injection) is approved by the FDA and EMA for the treatment of adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes. In a phase 3 study (NCT01696084) in patients (pts) aged 60-75 y with newly diagnosed high-risk/secondary AML, CPX-351 demonstrated significantly longer overall survival (OS) and higher rates of remission and hematopoietic cell transplant (HCT) vs conventional 7+3, with a comparable safety profile. To better understand the impact of treatment on outcomes in pts who did not undergo HCT, this exploratory analysis evaluated outcomes in the subgroup who achieved complete remission (CR) or CR with incomplete neutrophil or platelet recovery (CRi) with CPX-351 vs 7+3 but did not undergo HCT. Methods: Pts were randomized 1:1 to receive ≤2 induction cycles of CPX-351 (100 units/m 2 [C 100 mg/m 2 + D 44 mg/m 2 ] as a 90-min infusion on Days 1, 3, 5 [2nd induction: Days 1, 3]) or 7+3 (C 100 mg/m 2 /d continuously for 7 d + D 60 mg/m 2 on Days 1-3 [2nd induction: 5+2]). Pts achieving CR or CRi could receive up to 2 consolidation cycles. Pts could receive HCT at the physician’s discretion. Results: CR+CRi was achieved by 73/153 (48%) pts with CPX-351 vs 52/156 (33%) with 7+3; of these pts, 33/73 (45%) vs 28/52 (54%) did not subsequently undergo HCT. The baseline characteristics of these pts were generally balanced between arms; however, the CPX-351 arm had more male pts vs 7+3 (64% vs 43%) and pts with ECOG PS of 1 (82% vs 54%), and fewer pts with antecedent MDS and HMA exposure (21% vs 39%). Median OS was longer with CPX-351 vs 7+3 (14.72 vs 7.59 mo; HR = 0.57 [95% CI: 0.31-1.03]; Table). There was no early mortality by Day 60 in either arm (see Table for additional data). Conclusions: CPX-351 improved median OS vs 7+3 in pts who achieved CR+CRi but did not undergo HCT, suggesting a treatment benefit with CPX-351 even among pts who do not undergo HCT. The CPX-351 safety profile in this subgroup was consistent with the overall study population and known profile of 7+3. Clinical trial information: NCT01696084 . [Table: see text]
Impact of body composition on toxicity and pathological complete response in locally advanced breast cancer (BC).
Authors: Laura Sofia Munoz-Arcos, Jessica Mayer, Orli Haken, Jessica Goldman, Joseph A. Sparano, Jesus Del Santo Anampa Mesias
Journal: Journal of Clinical Oncology (2020)

593 Background: Obesity, defined as body mass index (BMI) &gt; 30 kg/m 2 , has been associated with inferior outcomes in localized breast cancer (BC), including lower pathological complete response (pCR) to neoadjuvant chemotherapy (NAC). High BMI is usually associated with excess adipose tissue (AT), but also reflects skeletal muscle (SM) mass. Low SM mass (sarcopenia) has also been associated with inferior outcomes and more chemotherapy-associated toxicity. We aimed to evaluate the association of BMI, AT and SM tissue with pCR and toxicity after NAC for stage II-III breast cancer (BC). Methods: 191 patients with stage II-III BC received NAC, had information regarding baseline BMI, toxicity and pCR to NAC at surgery, and, had abdominal computerized tomography (CT) prior to NAC. Total AT (TAT), visceral AT (VAT), subcutaneous AT (SAT), SM area (SMA) and SM density (SMD) were measured by CT at the L3 level using the TOMOVISION software. SM index (SMI) was calculated (SMA/height) to assess for sarcopenia (SMI &lt; 40). Association linking BMI, SAT, VAT, SMA and SMD to pCR and severe toxicity (ST ≥ grade 3) was evaluated using logistic regression models. Results: Patients were predominantly black (51%) with a median age of 54 years (interquartile range = 45-63). pCR was achieved in 31% (60/191) of patients. Of those, 47% (n = 28/60), 40% (n = 24/60) and 13% (n = 8/60) corresponded to HER2(+), triple negative, and hormone receptor-HR(+)/HER2(-) tumors, respectively. ST occurred in 38% (n = 73/191) of patients. Obesity and sarcopenia were present in 52% (n = 100/191) and 14% (n = 27/191) of patients, respectively. There was a statistically significant association between VAT and pCR (median VAT 95.3 cm 2 vs. 121.8 cm 2 in the pCR vs. no-pCR groups, respectively, p = 0.03). This association remained after adjusting for age, race, tumor grade, stage, BMI, SMD, HR and HER2 status (p = 0.04). There was a statistically significant association between SMA and ST (mean SMA 123 cm 2 vs. 130 cm 2 in the ST vs. no-ST groups, respectively, p = 0.03). This association disappeared after adjusting for age, race, BMI, VAT, SAT, and SMD (p = 0.21). Conclusions: This study provides evidence that in patients with stage II-III BC receiving NAC, excess VAT is associated with significantly lower pCR rates, and low SMA is associated with ST. Additional research is needed to elucidate the pathophysiologic mechanisms contributing to these associations.
Juvenile myoclonic epilepsy
Authors: 王道强, 刘建稳, 张卫华, 李支援
Journal: BMJ (2007)

青少年肌阵挛性癫痫(juvenile myoclonic epilepsy,JME)是一种以晨起肌阵挛、全身强直-阵挛发作(GTCS)为临床特征的特发性全身性癫痫综合征,有时伴有失神发作,约占全部癫痫的5%～11%[1]。
中华医学会全科医学分会第六届学术年会纪要
Authors: 杨秉辉
Journal: BMJ (2009)

中华医学会全科医学分会第六届学术年会于2008年11月8日至9日在江苏省南京市举行(图1).此次会议由江苏省医学会与南京医科大学承办.大会在南京华东饭店举行,来自全国各地的到会代表共200余人,提交论文100多篇.大会邀请了多位著名专家与会做专题演讲,还邀请了美国爱达荷州立大学附属医院的Smith医师及台湾家庭医学会、台湾大学医学院的刘文俊医师与会演讲.澳门家庭医学会主席官世海医师也出席了大会。
Oncological outcomes of 356 patients undergoing salvage focal ablative HIFU or cryotherapy following radiation failure.
Authors: Deepika Reddy, Taimur T. Shah, Marieke van Son, Stephanie Guillaumier, Feargus Hosking-Jervis, Tim Dudderidge, Stuart McCracken, Raj Nigam, Richard Hindley, Neil McCartan, Naveed Afzal, Henry Lewi, Raj Persad, Jaspal Virdi, Clement Orczyk, Caroline Moore, Manit Arya, Mark Emberton, Mathias Winkler, Hashim Uddin Ahmed
Journal: Journal of Clinical Oncology (2020)

5582 Background: Patients that have previously failed radiotherapy for prostate cancer is usually limited to systemic therapy due to morbidity from salvage prostatectomy. We reviewed the outcomes following focal salvage ablative therapy with HIFU or cryotherapy within the UK’s HEAT and ICE registries. Methods: 356 consecutive patients underwent focal ablative treatment after initial radiation treatment failure (28/1/2004-1/10/2019, 194 (54.5%) underwent HIFU (posterior recurrence) and 162 (45.5%) underwent cryotherapy (mostly anterior or T3b). Primary outcome was failure-free survival (FFS) defined as no systemic therapy, whole-gland treatment, metastases or prostate cancer-specific death. Secondary outcomes were adverse events and overall survival. Results: Median (IQR) age was 69years (65-73) and PSA (IQR) was 4.0ng/ml (1-7-7.2). Overall median (IQR) follow-up was 41.3 months (21.4-58.5). Quadrant ablation was performed in 128 (36.0%), hemi-ablation performed in 64 (18.0%), hockey-stick in 5 (1.4%) and 159 (43.8%) had unknown ablative patterns. Due to histological or MRI proven recurrence/residual disease, 31 (8.7%) underwent further focal salvage re-treatment. FFS (95%CI) at 3 and 6 years were 81% (76-87%) and 75% (68-83%) respectively. Median (IQR) time to failure was 15.5 months (19.7). Overall survival (95%CI) at 3 and 6 years were 97% (95-100%) and 88% (81-96%) respectively. Prostate-specific mortality was 2.8%. Overall 3 (0.8%) patients were managed for fistula formation, 16 (4.5%) were treated for UTIs. Conclusions: Salvage focal ablative therapy for radio-recurrent prostate cancer is safe and provides good short to medium-term oncological control. The FORECAST study is awaited to further determine oncological outcomes in this cohort.
Treating obesity as primary prevention of cancer.
Authors: Chowdhury Ferdous, Tareq Islam
Journal: Journal of Clinical Oncology (2020)

e13556 Background: Prevalence of obesity in Hispanic population has been increasing. Obesity is a ‘super carcinogen’ and largely modifiable factor. We hypothesize due to current increase in prevalence of obesity there will be similar change in trend of malignancy among Hispanics and treating obesity can lead to decrease prevalence of both health conditions. Methods: National Health and Nutrition Examination Survey (NHANES) from year 1999 through 2016 was used to analyze obesity prevalence across different races. Surveillance Epidemiology and End Result (SEER) data was analyzed for racial distribution of overall and different kind of malignancies stratified by different races from 1999 through 2016. Differences of prevalence among different groups were calculated using likelihood ratio. Results: After exclusion criteria final sample size was 48,816 from NHANES and 6,868,226 from SEER dataset. Prevalence of obesity steadily increased in all races with highest change in Hispanics (31.7% in 1999-2000 to 47.3% in 2015-2016). Proportion of Hispanics with cancer also steadily increased from 7.5% in 1999-2000 to 11.3 in 2015-2016 in SEER dataset. States with high Hispanic population (New Mexico, California and New Jersey) had higher proportion of breast cancer (15.4%) compared to other states (14.5%) (p-value &lt; 0.0001). Conclusions: Upward trend of obesity and malignancy is evident among Hispanic population. Hispanic populated states are showing higher prevalence of certain metabolically active malignancies. This increase in prevalence can be explained by “Migration Effect”. By intervening obesity 18% population attributable factor (PAF) is achievable. Opportunity exists to change this increasing trend in cancer epidemiology by treating obesity as primary prevention.
Serum sialic acid levels in diagnosis and monitoring of malignant tumor
Authors: Hai-sheng Ji, Bo Li, Ai Yang, Jia-xue Wu
Journal: BMJ (2010)

Serum sialic acid (SA) levels were detected by neuraminidase method in 366 patients with malignant tumor, 40 patients with benign diseases and 40 healthy subjects.For 277 malignant tumor patients, serum SA levels were monitored before and after treatment.The serum SA levels in malignant tumor group were significantly higher than those in benign diseases and control groups (P ＜0.01 ), but there were no differences between normal and benign groups (P ＞0.05 ).Serum SA levels were decreased in malignant tumor patients with remission and stable disease after treatment.In remission or stable patients the decrease of serum SA levels occurred in the first three months and no changes were found from the fourth to sixth month; meanwhile SA levels were elevated in patients with instablc condition.

Key words: 
Sialic acid;  Monitoring
重视大肠癌的早期诊断
Authors: 蔡宏, 莫善兢
Journal: BMJ (2005)

大肠癌包括结肠癌和直肠癌,是近二、三十年来发病数和死亡数在世界大多数国家和地区上升最快的肿瘤之一.近年的流行病学资料显示[1],大肠癌已上升为全球第3位最常见的癌症,2000年全世界有70万人患大肠癌,50万人死于大肠癌.发达国家如美国2005年估计将有新发大肠癌患者145 290人,占全年新发癌症总数的10.6%,仅次于前列腺癌、肺及气管癌和乳腺癌而位居第4位;估计大肠癌死亡人数56 290人,占全年癌症死亡总数的9.9%,仅次于肺及气管癌而位居第2位[2]。
Meta-analysis and systematic review of the cardiotoxicity of TAS-102.
Authors: Carlos Alberto Lopez, Elham Azimi-Nekoo, Su Yun Chung, James Newman, Janice Shen, Wasif M. Saif
Journal: Journal of Clinical Oncology (2020)

e16053 Background: Fluoropyrimidines such as 5-FU and capecitabine are known to be cardiotoxic drugs. TAS-102 (trifluridine-tipiracil) is a novel oral fluoropyrimidine that was recently FDA approved to treat gastric and colon cancer. However, the incidence of cardiac related events of TAS-102 is not fully ascertained. We performed a meta-analysis and systematic review to determine the incidence of cardiotoxic events associated with TAS-102. Methods: We performed a literature search through PubMed, Embase, and Web of Science to identify any publications in any language up to December 31 st , 2019 where TAS-102 (and equivalent terms such as “trifluridine-tipiracil” and “Lonsurf”) was used. These were then manually reviewed to identify any publications reporting cardiac events. Randomized controlled trials (RCTs) were included for meta-analysis to determine the incidence of cardiotoxic events, which were summarized as pooled odds ratios (OR) when compared to placebo. Non-randomized, non-controlled clinical trials (phase I and phase II studies) were included in the systematic review but excluded from the pooled OR calculation. Results: 869 publications were identified in the initial literature search, of which 17 trials (3 Phase III studies, 6 Phase II studies, and 8 phase I studies) met inclusion criteria. A total of 1,877 patients among 4 RCTs were included in the meta-analysis. Compared with placebo, TAS-102 did not increase the risk of myocardial infarction (OR 1.97 95% CI [0.22-17.89]), hypertension (OR 0.73 95% CI [0.37, 1.44]), palpitations (OR 1.51 95% CI [0.30, 7.56]), cardio-pulmonary arrest (OR 0.83 95% CI [0.11-6.32]), or syncope (OR 1.50 95% CI [0.06-37.14]). Among the 1,252 patients receiving TAS-102, the overall incidence of cardiovascular events was low, with hypertension being the most common side effect (21 events), followed by palpitations (6 events), cardiopulmonary arrest (2 events), and myocardial infarction (3 events), though there was no statistically significant increased risk compared to placebo. No deaths were reported. Conclusions: Unlike other fluoropyrimidines, TAS-102 appears to be a cardiogentle drug, with no increased risk of cardiac events compared to placebo. Since fluoropyrimidines remain the backbone of treatment for gastrointestinal malignancies, TAS-102 can offer an alternative to patients who developed cardiotoxicities from other agents. Prospective studies with consideration of cardiac risk factors are required.
孕妇登记
Authors: 周健, 段涛
Journal: BMJ (2007)

从怀孕到分娩需经历280天,再经产褥期使身体恢复正常又需42天,在这个很长的生理过程中,每个阶段都有其特定的保健要求,而各个阶段又都是息息相关的,常常涉及到多个医疗保健单位,如基层机构进行访视和一般检查,医院负责接产和处理高危妊娠孕产妇。
Development CRISPR-Cas12-based rapid EGFR mutation detection kit.
Authors: Kei Kunimasa, Yuya Bando, Miyako Shiraishi, Emi Aizawa, Kazumi Nishino, Motohiro Tamiya, Takako Inoue, Hanako Kuhara, Hayato Kawachi, Kika Kuno, Fumio Imamura, Shigenori Iwai, Toru Kumagai, Keiichiro Suzuki
Journal: Journal of Clinical Oncology (2020)

e13669 Background: Recently, several cancer gene panel tests have been developed to determine many driver mutations including lung cancer simultaneously. However, the current next-sequencing based platform is not ideal testing method in the clinical practice due to the high examination cost and the time required for the result to reach the field. By refining recently reported CRISPR-Cas-based nucleic acid detection methods, we developed a novel CRISPR-Cas12 family based rapid-detection kit for targetable EGFR mutations in non-small lung cancer (NSCLC) patients. Methods: To develop a powerful CRISPR-based testing method, we focused on unique Cas12 family proteins which contain a single RuvC nuclease domain that cleave target double-stranded DNA adjacent to protospacer adjacent motif (PAM) sequences as well as non-target single-stranded DNA (ssDNA) collaterally. We purified 6 Cas12 family proteins (Cas12a, Cas12c1, Cas12c2, Cas12g, Cas12i1, and Cas12i2) as well as two types of target-defined guide RNA for EGFR Ex.19 del(E746-A750) and L858R mutations. The target sequences including EGFR Ex.19(E746-A750) and L858R mutations were amplified from EGFR mutated cell lines, FFPE lung cancer tissues or cell free DNA (cfDNA) of NSCLC patients using PCR with PrimeSTAR GXL DNA polymerase (Takara, Shiga, Japan) or isothermal recombinase polymerase amplification (RPA) with TwistAmp Basic (TwistDx, Cambridge, UK). CRISPR-Cas12-based cleavage assay was conducted in a reaction buffer consisting of 10 nM Cas12 proteins, 10 nM purified guide RNA, 0.4nM target DNA, and 50 nM collateral ssDNA (quenched fluorescent DNA reporter) in a 20 μl volume at 37 °C for 1 h. The excited fluorescence, which is an indicator of the presence of target cancer mutation, was measured by Synergy H1 hybrid Multi-Mode Reader (BioTek, Vermont, USA). For simpler instrument-free and portable detection lateral flow readouts were also developed and tested using Milenia HybriDetect1 kit (TwistDx). Results: Cas12a, Cas12i1, Cas12i2-based assays successfully detected the EGFR Ex.19 del(E746-A750) and L858R mutations from PCR and RPA products. Lateral flow readout kit could also detect EGFR Ex.19 del (E746-A750) mutation from cfDNA derived from NSCLC patients. It took about 3 hours from plasma collection to DNA extraction, RPA, and measurement with the kit. Conclusions: CRISPR-Cas based lateral flow readout kit can detect EGFR mutation at an unprecedented pace with low cost. Our developed system will be an innovative testing tool for lung cancer patients with low cost, rapid, multiplexable, and noninvasive procedure.